Ardelyx (ARDX)
(Delayed Data from NSDQ)
$5.99 USD
-0.05 (-0.83%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $6.00 +0.01 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.99 USD
-0.05 (-0.83%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $6.00 +0.01 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Zacks News
Wall Street Analysts Think Ardelyx (ARDX) Could Surge 65.4%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Ardelyx (ARDX) points to a 65.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Key Metrics Tell Us About Ardelyx (ARDX) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 30% and 31.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -33.33% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Suncor's (SU) Q4 Earnings Preview: Key Things to Consider
by Zacks Equity Research
Suncor Energy (SU) beat the Zacks Consensus Estimate for earnings in each of the last four quarters.
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Marathon (MRO) Q4 Earnings on Deck: Here's How It Will Fare
by Zacks Equity Research
Lower commodity price realizations and the increase in costs are likely to have impacted the fourth-quarter earnings of Marathon Oil (MRO).
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Ardelyx (ARDX) Could Rally 34.84%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ardelyx (ARDX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Ardelyx (ARDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Eli Lilly (LLY) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 0.81% and 5.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.
Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 127.27% and 155.31%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.